External Cooling in Septic Shock Patients (sepsis-cool)
Primary Purpose
Septic Shock
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
External cooling
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock focused on measuring Vasopressor, Epinephrine, Norepinephrine, Cooling, Fever, ICU
Eligibility Criteria
Inclusion Criteria:
- Documented or suspected infection
- Body temperature > 38.3°C
- Persistent hypotension despite fluid resuscitation and need for vasopressor infusion to maintain mean arterial pressure > 65 mmHg.
- Invasive mechanical ventilation
- Intravenous sedation
Exclusion Criteria:
- Temperature > 41°C
- Age < 18 years
- Pregnancy
- Continuous renal replacement therapy
- Paracetamol or NSAI administration within 6 hours before inclusion
- Need for paracetamol and/or NSAI therapy during the study period
- Burns or Lyell syndrome
Sites / Locations
- CHU Henri Mondor
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
A
B
Arm Description
Outcomes
Primary Outcome Measures
Number of patients with a decrease in the dose of vasopressors of 50% 48 hours after enrolment
Secondary Outcome Measures
Maximal dose of vasopressors
SOFA score evolution
Number of vasopressor free days in the ICU
Full Information
NCT ID
NCT00527007
First Posted
September 6, 2007
Last Updated
July 21, 2010
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT00527007
Brief Title
External Cooling in Septic Shock Patients
Acronym
sepsis-cool
Official Title
Impact of External Cooling in Septic Shock Patients
Study Type
Interventional
2. Study Status
Record Verification Date
August 2008
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The rapidity of the resolution of cardiovascular failure has a strong impact on septic shock patients' outcome. The aim of this multicenter randomized controlled trial is to determine whether external cooling might accelerate improvement in cardiovascular function.
Detailed Description
Patients suffering from septic shock need fluid resuscitation and vasopressor therapy for restoring cardiovascular function. Corticosteroids and activated protein C have been both proposed for vascular tone improvement. While external cooling is largely used in ICU febrile patients, benefits and risks of fever treatment during sepsis have been rarely studied. Surveys show that external cooling is usual care applied by nurses themselves without medical order.
The control of thermal balance might decrease cardiac output and oxygen consumption, and reduce serum lactate concentration. However some animal studies have suggested that fever might be essential for host defence. This trial compares two strategies of fever management on vasopressor dependence in septic shock patients. In the treatment group, external cooling is applied to normalize the body temperature between 36°5 C and 37°C, while control patients receive any fever treatment. The goal for mean arterial pressure is the same in the two groups and vasopressor withdrawal is determined by similar algorithm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
Vasopressor, Epinephrine, Norepinephrine, Cooling, Fever, ICU
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Title
B
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
External cooling
Intervention Description
External cooling
Primary Outcome Measure Information:
Title
Number of patients with a decrease in the dose of vasopressors of 50% 48 hours after enrolment
Time Frame
48 hours after enrolment
Secondary Outcome Measure Information:
Title
Maximal dose of vasopressors
Time Frame
within 48 hours after enrolment
Title
SOFA score evolution
Time Frame
on Day 3, Day 7, Day 14
Title
Number of vasopressor free days in the ICU
Time Frame
during the study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Documented or suspected infection
Body temperature > 38.3°C
Persistent hypotension despite fluid resuscitation and need for vasopressor infusion to maintain mean arterial pressure > 65 mmHg.
Invasive mechanical ventilation
Intravenous sedation
Exclusion Criteria:
Temperature > 41°C
Age < 18 years
Pregnancy
Continuous renal replacement therapy
Paracetamol or NSAI administration within 6 hours before inclusion
Need for paracetamol and/or NSAI therapy during the study period
Burns or Lyell syndrome
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frederique SCHORTGEN, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Henri Mondor
City
Creteil
ZIP/Postal Code
94000
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
26202042
Citation
Schortgen F, Charles-Nelson A, Bouadma L, Bizouard G, Brochard L, Katsahian S. Respective impact of lowering body temperature and heart rate on mortality in septic shock: mediation analysis of a randomized trial. Intensive Care Med. 2015 Oct;41(10):1800-8. doi: 10.1007/s00134-015-3987-7. Epub 2015 Jul 23.
Results Reference
derived
Learn more about this trial
External Cooling in Septic Shock Patients
We'll reach out to this number within 24 hrs